<DOC>
	<DOCNO>NCT00318656</DOCNO>
	<brief_summary>A good glycemic control associate less complication ( cardiac disease , blindness , etcetera ) type 2 diabetic patient . The objective study rosiglitazone may lead regular glycemic pattern less hyperglycemia hypoglycemia episode sulphonylurea ( glimepiride ) .</brief_summary>
	<brief_title>24-Hour Glycemia : Rosiglitazone Versus Glimepiride In Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Males female age 40 80 year Diagnosis type 2 diabetes mellitus least 6 month Body mass index ( BMI ) ≥25kg/m2 7 % ≥HbA1c ≤ 9 % visit 2 Treatment metformin 1.7g/day 3g/day least 12 week prior visit 1 Female subject must nonpregnant , postmenopausal , surgically sterile use effective contraceptive measure Written inform consent Use oral antidiabetic drug metformin within 12 week prior screen Significant hypersensitivity thiazolidinediones sulfonylureas compound similar chemical structure Subjects require use insulin glycaemic control time past subject history metabolic acidosis include diabetic ketoacidosis Subjects clinically significant ongoing oedema history oedema 12 month prior visit 1 Subjects history severe hypoglycaemia Anemia define haemoglobin concentration &lt; 11.0g/dL male &lt; 10.0g/dL female Renal disease renal dysfunction , e.g . suggest serum creatinine level ≥135µmol/L male ≥110µmol/L female Presence clinically significant hepatic disease ( i.e . ALT , AST , total bilirubin alkaline phosphatase &gt; 2.5 time upper limit normal reference range ) Congestive heart failure ( NYHA class I IV ) , unstable severe angina , recent myocardial infarction Subjects chronic disease require periodic intermittent treatment oral intravenous corticosteroid Female lactating , pregnant , plan become pregnant Any clinically significant abnormality identify screen judgement investigator make subject unsuitable inclusion study ( e.g . physical examination , laboratory test , ECG , ... ) Use investigational agent within 30 day 5 halflives ( whichever longer ) prior enrolment study Active alcohol , drug medication abuse within last 6 month condition would indicate likelihood poor subject compliance Subjects willing comply procedure describe protocol .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>rosiglitazone</keyword>
	<keyword>metformin</keyword>
	<keyword>glimepiride</keyword>
	<keyword>glycemia</keyword>
</DOC>